Sysmex Corporation (HQ: Kobe, Japan; President: Iwane Matsui) announced that it has launched “HISCL™ p-Tau217 Assay Kit for Research Use” (“the Product”), a reagent for research purposes to identify a biomarker1 related to Alzheimer’s disease, namely blood p-Tau2172 levels, in Europe in April 2026. Following the launch in Europe, the Product will be rolled out sequentially in Japan, the United States, South Korea, and Taiwan, contributing to accelerated global data acquisition for Alzheimer’s disease research.

Also Read: UAE Healthcare Sector Reaffirms Readiness and Unity in Line with National Pride Campaign

In research on Alzheimer’s disease and the development of new treatments, there is a need to establish biomarkers that can accurately assess pathological changes in the brain. However, conventional brain imaging and cerebrospinal fluid (CSF) tests are not only limited to facilities where they can be performed, but are also invasive and costly, placing a significant burden on patients. This has posed challenges in scaling up research and accumulating data. Against this backdrop, minimally invasive and simple evaluation methods using blood biomarkers are attracting attention as methods that are easier to implement, and these are expected to improve the efficiency of research and development.

The Product is an assay kit for research use that enables fully automated measurement of p-Tau217, a blood biomarker that has attracted attention in research for its association with pathological changes in Alzheimer’s disease, using the HISCL™-5000/HISCL™-800, Automated Immunoassay System (“HISCL-Series”).5 The automated measurement capabilities of the HISCL-Series will enable research institutions and pharmaceutical companies to conduct evaluations using collected blood samples more quickly and at larger scale, supporting data acquisition in biomarker research and drug discovery research.

Click here to join our WhatsApp channel here